“Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Heavily Pretreated Patients With Hematological Malignancies”. Hematology Meeting Reports 1, no. 8 (June 3, 2009). Accessed August 12, 2025. https://journals.pagepress.org/hmr/article/view/297.